Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Immtech Conducts Joint US/China Trials for Pneumonia Drug

publication date: Nov 30, 2007

Immtech Pharmaceuticals has enlisted Jubo Liu, PhD, to serve as Development Liaison for Clinical Trials in China. Currently, Immtech is conducting a Phase III trial of pafuramidine as a treatment for pneumocystis pneumonia (PCP), a fungal infections affecting patients with compromised immune systems. This includes people with HIV/AIDS and transplant patients. An estimated 1 million people worldwide suffer from the disease, while another 5 million people are treated prophylactically for the disease. The China State Food & Drug Administration recently granted Fast Track Status to the Phase III trial of pafuramidine. More details...

Stock Symbols: (AMEX: IMM) (NYSE: PRX) (NSDQ: VRTX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital